PeptidePedia The community reference

Talk:Triple agonist

Discussion page·2 threads·no archives

This article is within the scope of the pharmacology working group.

This is the discussion page for the article Triple agonist. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.

Ratio comparisons across publicationsResolved

The warning about assay-dependent ratios matters more here than for dual agonists because three numbers invite more comparison. — ReceptorRhoda (talk) 09:35, 21 January 2026 (UTC)

Stated with that reasoning attached rather than as a bare repetition of the dual-agonist caveat. ✓ Done — GsCouplingGil (talk) 13:10, 21 January 2026 (UTC)

Resolved. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.

Predicted failure modeDone

Calling the early glucose rise the design's predicted failure mode rather than an unexpected finding is accurate and more informative. — RetatrutideRuben (talk) 10:25, 26 April 2026 (UTC)

And it explains the unusually long escalation schedules. ✓ Done — EscalationEira (talk) 14:00, 26 April 2026 (UTC)

Done. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.
This page was last edited on 26 April 2026, by EscalationEira. Text is available under the PeptidePedia Wiki Content Licence (PPCL-BY-SA 4.0).